Azitra Inc (AZTR)

BRANFORD, Conn., Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Azitra's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. As previously reported, on October 1, 2025, Azitra received a letter from the NYSE American stating that Azitra is not in compliance with the minimum stockholders' equity requirement of Section 1003(a)(ii) of the Company Guide requiring stockholders' equity of $4.0 million or more if Azitra has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years. Azitra must regain compliance with the continued listing standards by April 1, 2027. If Azitra is not in compliance with the continued listing standards by April 1, 2027, or if Azitra does not make progress consistent with the Plan during the plan period, NYSE Regulation staff will initiate delisting proceedings as appropriate. Azitra will continue its listing on NYSE American during the plan period and will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan until it has regained compliance. Azitra is assessing and exploring multiple funding avenues and is committed to achieving compliance with the Exchange's requirements. Receipt of the notice from the Exchange has no immediate effect on the listing or trading of Azitra's common stock on the Exchange, and does not affect Azitra's business, operations or reporting requirements with the U.S. Securities and Exchange Commission.

Gommosa

Sbrocca

entrato per swingata intraday pmc 1,26

opinioni?

game over

io ci provo in chiusura

entrato....

da oltre +100% a rossa ormai non mi sorprende più niente

Che tonfo. Quindi ora faranno rs pure

Sono usxito in tempo… avete novità sull’offering?

Offering

C’è qualcuno qui?

Otc

Pure in negativo

Non va su nenmeno con queste notizie..

Non ci sono molto dati su questa azienda mi pare. I farmaci sono lontani.. fase 2 nemmeno

Andata

proviamo a resistere, l'importante è che non fallisca. ne ho 4250 ad 1,3 dollari...io credo che riparta...

Un bagno di sangue

Non sale mai

game over

tranquillo

pensate che l'azione sia a rischio fallimento?

Si sta formando un brutto grafico